Project Grant R01AI202976
Award Date 8/12/26
Completion Date 7/31/31
Dollars Obligated $668K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...
- The National Institute of Allergy and Infectious Diseases awarded Virginia Polytechnic Institute & State University $808,607 on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize AI-designed antimicrobial peptides targeting ESKAPE pathogens. The project integrates artificial intelligence, machine learning, chemical approaches, and computational tools to develop peptide-based therapeutics against multidrug-resistant bacteria including...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Virginia $253,445 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanistic insights into enteropathogen-mediated MUC3/4 signaling disruption and intestinal inflammation onset. The research uses human intestinal organoids to examine novel mechanisms triggering intestinal inflammation and mucosal...
- The National Institute of Allergy and Infectious Diseases awarded Virginia Polytechnic Institute & State University $199,059 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study competitive microbial interactions driving pathogen adaptation during biofilm-associated infections. The research addresses polymicrobial chronic wound infections, which are predicted to affect 2 percent of the U.S. population and cost the healthcare system up to $97...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $713,396 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the molecular mechanisms of protective lung resident memory T cells. The project examines how lung tissue-resident memory CD8+ T cells provide broad-spectrum protection against influenza infection, including heterologous protection against variant strains. The research focuses on a...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $444,125 to the University of Virginia on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode immune responses during sequential rhinovirus infections. The recipient will conduct a comprehensive analysis of immune cells and anti-viral mediators in blood and nasal specimens collected during sequential homotypic and heterotypic...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $201,875 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate a novel family of alpha-helical peptides that regulate nitrogen metabolism and virulence in pathogenic Enterobacteria, particularly enteroaggregative E. coli (EAEC). The research employs human intestinal organoids alongside infection and fitness mouse models to elucidate the regulatory...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,990 on April 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and target bacterial and genetic superspreaders of antimicrobial resistance genes in hospital ecosystems. The research investigates mechanisms of antibiotic resistance gene transfer within hospital environments, particularly focusing on carbapenemase resistance spreading through wastewater and...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $609,185 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a physics-informed machine learning model for elucidating the therapeutic mechanisms of bacterial therapeutics against Clostridium difficile infection. The funded work centers on creating a Neural Species Mediator model to systematically understand how living bacterial therapeutics function in the...
- The National Institute of Allergy and Infectious Diseases awarded University of New Haven, Incorporated $126,351 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop machine learning approaches for analyzing microbiome dynamics in ventilator-associated pneumonia. The project addresses VAP diagnostic delays and poor sensitivity in current clinical methods by developing interpretable machine learning models that integrate 16S rRNA sequencing...